Etoposide/ifosfamide/cisplatin regimens in metastatic non-small cell lung cancer

E. A. Perez, David R Gandara

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Although non-small cell lung cancer has long been considered poorly responsive to chemotherapy, there are now a number of chemotherapeutic agents with reproducible activity in this disease, including cisplatin and ifosfamide. Another agent, etoposide, has been rationally incorporated into combination regimens for this disease based on demonstrated preclinical synergy. We review recent studies combining these three agents in the treatment of metastatic non-small cell lung cancer as well as prospects for further development.

Original languageEnglish (US)
Pages (from-to)2-5
Number of pages4
JournalSeminars in Oncology
Volume21
Issue number3 SUPPL. 4
StatePublished - 1994

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Etoposide/ifosfamide/cisplatin regimens in metastatic non-small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this